Saxagliptin - AstraZeneca

Drug Profile

Saxagliptin - AstraZeneca

Alternative Names: BMS-477118; Onglyza; OPC-262

Latest Information Update: 08 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; Bristol-Myers Squibb; Otsuka Pharmaceutical
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Dipeptides; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Nov 2017 Bristol-Myers Squibb and AstraZeneca completes a phase III trial for Type-2 diabetes mellitus (Combination therapy) in USA, Czech Republic, Denmark, Germany, Hungary, Mexico, Poland, Romania, South Africa, Spain and Sweden (PO) (NCT02551874)
  • 11 Oct 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Combination therapy, In children, In adolescents) in USA, Poland, Finland (PO) (NCT03199053) (EudraCT2015-005042-66)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top